(PharmaNewsWire.Com, November 09, 2021 ) According to research report the Structural Heart Devices Market is expected to reach USD 19.6 billion by 2027 from USD 10.4 billion in 2019, at a CAGR of 8.2%.
The rising prevalence of structural heart diseases, regulatory approvals for new and advanced structural heart devices, favorable reimbursement scenario for structural heart procedures & devices, and increasing awareness about structural heart diseases are the major factors driving the growth of the structural heart devices market.
Premium Insights
> Structural Heart Devices: Market Overview > Geographic Analysis: Structural Heart Devices Market, By Repair Procedures > Structural Heart Devices Market, By Procedure, 2018 vs 2023 > Structural Heart Devices Market, By Product, 2018 vs 2023 > Geographic Snapshot of the Structural Heart Devices Market
On the basis of procedure, the market has been broadly segmented into replacement procedures and repair procedures. The replacement procedures segment is further segmented into TAVR (transcatheter aortic valve replacement) procedures and SAVR (surgical aortic valve replacement) procedures, while the repair procedures segment is subdivided into closure procedures, annuloplasty, valvuloplasty, and TMVR procedures. The replacement procedures segment is expected to account for the largest share of the Structural Heart Devices Market in 2018. This can be attributed to the long-term durability of these procedures and the widespread preference for transcatheter replacement.
On the basis of products, the Structural Heart Devices Market is segmented into heart valve devices, occluders and delivery systems, annuloplasty rings, other devices, and accessories. The heart valve devices segment is further subdivided into transcatheter heart valves and surgical heart valves. The heart valve devices segment is expected to account for the largest market share in 2018. The growing number of transcatheter aortic valve replacement procedures performed across the globe, the efficacy and durability of these products, and the growing number of regulatory approvals for heart valve devices are some of the key factors supporting the growth of this product segment.
The major players operating in the structural heart devices market are Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK).
The geographic segments in this report include North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the structural heart devices market in 2018. The large share of this region in the global market is attributed to factors such as the rising prevalence of structural heart diseases, favorable reimbursement scenario for structural heart procedures and devices, technological advancements, and development of innovative devices.
The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as the rising geriatric population, favorable reimbursement scenario, increasing regulatory approvals, the presence of a large target patient population, increasing healthcare expenditure, implementation of government-funded insurance schemes, and the growing medical tourism industry in several APAC countries are expected to drive the growth of the Asia Pacific structural heart devices market.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
